Markets

Mineralys Therapeutics To Present Five Abstracts At American Heart Association Hypertension Scientific Sessions 2026,

Oct 1, 2026 · 04:06 PM ET· updated 7h ago

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney

Why It Matters

Mineralys will show five research studies about heart and kidney medicine. This shows the company is making progress on treatments people need.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

MLYS24.46

-0.67 (-2.67%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.